Oncternal Therapeutics (NASDAQ:ONCT) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Rating) in a research note issued to investors on Thursday. The brokerage issued a sell rating on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Brookline Capital Management reaffirmed a buy rating on shares of Oncternal Therapeutics in a report on Thursday, March 9th. Cantor Fitzgerald assumed coverage on shares of Oncternal Therapeutics in a research note on Thursday, December 22nd. They issued an overweight rating and a $4.00 price target on the stock. Finally, HC Wainwright reiterated a buy rating and issued a $7.00 price target on shares of Oncternal Therapeutics in a research note on Tuesday, March 14th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat, Oncternal Therapeutics presently has an average rating of Moderate Buy and an average price target of $5.50.

Oncternal Therapeutics Stock Down 8.2 %

Shares of ONCT stock traded down $0.06 on Thursday, reaching $0.66. The stock had a trading volume of 295,787 shares, compared to its average volume of 217,899. The firm’s 50-day moving average is $1.03 and its two-hundred day moving average is $1.00. Oncternal Therapeutics has a 12 month low of $0.66 and a 12 month high of $1.87.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Oncternal Therapeutics during the 1st quarter worth approximately $585,000. Vanguard Group Inc. grew its position in shares of Oncternal Therapeutics by 9.0% during the 1st quarter. Vanguard Group Inc. now owns 2,325,515 shares of the company’s stock worth $3,232,000 after purchasing an additional 192,189 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Oncternal Therapeutics by 44.4% during the 1st quarter. Renaissance Technologies LLC now owns 543,800 shares of the company’s stock worth $756,000 after purchasing an additional 167,268 shares in the last quarter. Mirabella Financial Services LLP acquired a new position in shares of Oncternal Therapeutics during the 1st quarter worth approximately $38,000. Finally, UBS Group AG grew its position in shares of Oncternal Therapeutics by 1,373.8% during the 2nd quarter. UBS Group AG now owns 166,298 shares of the company’s stock worth $184,000 after purchasing an additional 155,014 shares in the last quarter. Institutional investors and hedge funds own 16.66% of the company’s stock.

Oncternal Therapeutics Company Profile

(Get Rating)

Oncternal Therapeutics, Inc engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.